Researchers from Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), have identified a biomarker for Glioblastoma multiforme (GBM), an aggressive cancer of the brain.
The team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as
both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Glioblastoma multiforme (GBM), WHO classification name “glioblastoma”, is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells. Median survival with standard-of-care radiation and chemotherapy with temozolomide is just 15 months.
The ability to characterize disease specific exosomes in circulation will enable improved diagnosis to identify type and grade of these aggressive brain tumors and may additionally help to advance novel treatment strategies.
Read More: http://www.investorideas.com/CO/AEMD/news/2014/03191.asp
www.arogyada.in
